Schrodinger Inc

SDGR

Equity

ISIN null / Valor 51947209

NASDAQ (2025-11-21)

USD 16.47+0.86%

Schrodinger Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Schrodinger Inc is a company that focuses on reducing risk in drug discovery and development by selecting high-value targets with established human genetics or clinical validation. The company aims to solve design challenges and deliver value for patients through its therapeutics group. With a strong emphasis on innovation and scientific expertise, Schrodinger Inc plays a crucial role in advancing the field of pharmaceutical research and development.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Total revenue for Q2 2025 rose by 16% to $54.8 million, driven by a 15% increase in software revenue to $40.5 million and a 19% rise in drug discovery revenue to $14.2 million. Despite a decrease in software gross margin to 68%, the overall financial performance remained robust.

Operating Expenses and Net Loss

Operating expenses decreased by 6% to $79.1 million compared to Q2 2024, primarily due to lower R&D costs. Other income surged to $10.0 million from an expense of $1.2 million the previous year. The net loss narrowed to $43.2 million in Q2 2025 from $54.0 million in Q2 2024.

Strategic Developments

Schrödinger is advancing its clinical pipeline with Phase 1 data for SGR-1505 and expects initial data for SGR-3515 and SGR-2921 in Q4 2025. Additionally, the company expanded its research collaboration with Ajax Therapeutics and implemented organizational changes to enhance operational efficiency.

Summarized from source with an LLMView Source

Key figures

-19.1%1Y

-10.5%3Y

-72.8%5Y

Performance

63.7%1Y

65.8%3Y

65.7%5Y

Volatility